• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Conditional concordance-assisted learning under matched case-control design for combining biomarkers for population screening.条件一致性辅助学习在匹配病例对照设计下用于人群筛查中生物标志物的联合。
Stat Med. 2023 Apr 30;42(9):1398-1411. doi: 10.1002/sim.9677. Epub 2023 Feb 2.
2
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.血清视黄醇和类胡萝卜素浓度与前列腺癌风险:前列腺癌预防试验的结果。
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1507-15. doi: 10.1158/1055-9965.EPI-15-0394. Epub 2015 Aug 12.
3
Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.血清视黄醇与前列腺癌风险:前列腺、肺、结肠和卵巢癌筛查试验中的一项巢式病例对照研究
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1227-31. doi: 10.1158/1055-9965.EPI-08-0984. Epub 2009 Mar 31.
4
The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial.肺癌与前列腺癌风险和血清微量营养素之间的关联:β-胡萝卜素与视黄醇功效试验的结果与经验教训
Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):518-26.
5
Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study.在欧洲癌症与营养前瞻性调查研究中血浆类胡萝卜素、视黄醇、生育酚与前列腺癌风险
Am J Clin Nutr. 2007 Sep;86(3):672-81. doi: 10.1093/ajcn/86.3.672.
6
Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial.胡萝卜素与视黄醇功效试验中膳食补充剂的使用与前列腺癌风险
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2202-6. doi: 10.1158/1055-9965.EPI-09-0013.
7
Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort.血清或尿液中硒、生育酚、类胡萝卜素、视黄醇和15-异前列腺素F(2t)与前列腺癌风险的关联:多民族队列研究
Cancer Causes Control. 2009 Sep;20(7):1161-71. doi: 10.1007/s10552-009-9304-4. Epub 2009 Feb 11.
8
Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy.视黄醇、类胡萝卜素与前列腺癌风险:一项来自意大利的病例对照研究。
Int J Cancer. 2004 Nov 20;112(4):689-92. doi: 10.1002/ijc.20486.
9
Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.锌 α2-糖蛋白作为一种潜在的新型尿液生物标志物用于前列腺癌的早期诊断。
BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.
10
Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.二乙酰精胺是一种用于非小细胞肺癌的新型诊断前血清生物标志物,与表面活性蛋白原B具有相加性能。
J Clin Oncol. 2015 Nov 20;33(33):3880-6. doi: 10.1200/JCO.2015.61.7779. Epub 2015 Aug 17.

本文引用的文献

1
Combining biomarkers by maximizing the true positive rate for a fixed false positive rate.通过最大化固定假阳性率下的真阳性率来组合生物标志物。
Biom J. 2021 Aug;63(6):1223-1240. doi: 10.1002/bimj.202000210. Epub 2021 Apr 19.
2
Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint.基于学习的生物标志物辅助规则,以在风险约束下实现最佳临床获益。
Biometrics. 2020 Sep;76(3):853-862. doi: 10.1111/biom.13199. Epub 2019 Dec 25.
3
Estimating the receiver operating characteristic curve in matched case control studies.估算匹配病例对照研究中的受试者工作特征曲线。
Stat Med. 2019 Feb 10;38(3):437-451. doi: 10.1002/sim.7986. Epub 2018 Nov 22.
4
Combining multiple biomarkers linearly to maximize the partial area under the ROC curve.将多个生物标志物线性组合以最大化 ROC 曲线下的部分面积。
Stat Med. 2018 Feb 20;37(4):627-642. doi: 10.1002/sim.7535. Epub 2017 Oct 30.
5
Model-free scoring system for risk prediction with application to hepatocellular carcinoma study.用于风险预测的无模型评分系统及其在肝细胞癌研究中的应用。
Biometrics. 2018 Mar;74(1):239-248. doi: 10.1111/biom.12750. Epub 2017 Jul 25.
6
Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach.在ROC分析中定义最佳切点值:一种替代方法。
Comput Math Methods Med. 2017;2017:3762651. doi: 10.1155/2017/3762651. Epub 2017 May 31.
7
Robust risk prediction with biomarkers under two-phase stratified cohort design.在两阶段分层队列设计下利用生物标志物进行稳健的风险预测。
Biometrics. 2016 Dec;72(4):1037-1045. doi: 10.1111/biom.12515. Epub 2016 Apr 1.
8
Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies.在两阶段病例对照研究中,根据受试者工作特征曲线下面积评估和比较生物标志物。
Biostatistics. 2016 Jul;17(3):499-522. doi: 10.1093/biostatistics/kxw003. Epub 2016 Feb 16.
9
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.肝细胞癌的当前生物标志物:监测、诊断及预后预测
World J Hepatol. 2015 Feb 27;7(2):139-49. doi: 10.4254/wjh.v7.i2.139.
10
Optimal linear combinations of multiple diagnostic biomarkers based on Youden index.基于约登指数的多个诊断生物标志物的最佳线性组合。
Stat Med. 2014 Apr 15;33(8):1426-40. doi: 10.1002/sim.6046. Epub 2013 Dec 6.

条件一致性辅助学习在匹配病例对照设计下用于人群筛查中生物标志物的联合。

Conditional concordance-assisted learning under matched case-control design for combining biomarkers for population screening.

机构信息

Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas McGovern Medical School at Houston, Houston, Texas, USA.

Department of Biostatistics and Data Science, The University of Texas School of Public Health, Dallas, Texas, USA.

出版信息

Stat Med. 2023 Apr 30;42(9):1398-1411. doi: 10.1002/sim.9677. Epub 2023 Feb 2.

DOI:10.1002/sim.9677
PMID:36733187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121762/
Abstract

Incorporating promising biomarkers into cancer screening practices for early-detection is increasingly appealing because of the unsatisfactory performance of current cancer screening strategies. The matched case-control design is commonly adopted in biomarker development studies to evaluate the discriminative power of biomarker candidates, with an intention to eliminate confounding effects. Data from matched case-control studies have been routinely analyzed by the conditional logistic regression, although the assumed logit link between biomarker combinations and disease risk may not always hold. We propose a conditional concordance-assisted learning method, which is distribution-free, for identifying an optimal combination of biomarkers to discriminate cases and controls. We are particularly interested in combinations with a clinically and practically meaningful specificity to prevent disease-free subjects from unnecessary and possibly intrusive diagnostic procedures, which is a top priority for cancer population screening. We establish asymptotic properties for the derived combination and confirm its favorable finite sample performance in simulations. We apply the proposed method to the prostate cancer data from the carotene and retinol efficacy trial (CARET).

摘要

将有前途的生物标志物纳入癌症筛查实践以进行早期检测越来越受到关注,因为当前癌症筛查策略的性能并不令人满意。匹配病例对照设计通常用于生物标志物开发研究中,以评估生物标志物候选物的区分能力,旨在消除混杂效应。虽然生物标志物组合与疾病风险之间的假定对数联系并不总是成立,但匹配病例对照研究的数据通常通过条件逻辑回归进行分析。我们提出了一种条件一致性辅助学习方法,该方法是无分布的,用于确定最佳的生物标志物组合来区分病例和对照。我们特别关注具有临床和实际意义的特异性的组合,以防止无疾病的个体接受不必要的、可能具有侵入性的诊断程序,这是癌症人群筛查的首要任务。我们为推导出的组合建立了渐近性质,并在模拟中确认了其在有限样本中的良好性能。我们将所提出的方法应用于来自胡萝卜素和视黄醇疗效试验 (CARET) 的前列腺癌数据。